HLA typing for transplant market - Global Forecast To 2030
商品番号 : SMB-44874
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年5月 |
| ページ数 | 261 |
| 図表数 | 291 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
本レポートは、移植用HLAタイピング市場を、製品・サービス、技術、移植の種類、用途、エンドユーザー、地域の観点から分析しています。市場の成長に影響を与える主要な要因（推進要因や抑制要因など）を分析するとともに、市場機会とステークホルダーにとっての課題を分析し、市場リーダー企業の競争環境を詳細に解説しています。これは、各社の成長傾向、見通し、そして市場全体への貢献度に関するものです。また、主要5地域とそれぞれの主要国における市場セグメントの収益予測も提供しています。
The global HLA typing for transplant market is projected to reach USD 1.4 billion by 2030 from USD 1.1 billion in 2025, at a CAGR of 6.0% during the forecast period. The growth of the HLA typing market is being propelled by several key factors: the development of sophisticated HLA typing technologies, a rising demand for organ transplantation, strategic government efforts aimed at improving organ donation rates, and an expansion of research initiatives focused on HLA typing methodologies.
移植用HLAタイピングの世界市場は、2025年の11億米ドルから2030年には14億米ドルに達し、予測期間中に年平均成長率（CAGR）6.0%で成長すると予測されています。HLAタイピング市場の成長は、高度なHLAタイピング技術の開発、臓器移植の需要増加、臓器提供率向上に向けた政府の戦略的な取り組み、そしてHLAタイピング手法に焦点を当てた研究活動の拡大といった、いくつかの主要な要因によって推進されています。
By technology, the molecular assays segment accounted for the largest market share in 2024.
The HLA typing for transplant market, by technology, is segmented into non-molecular and molecular assays. In 2024, the molecular assay technologies segment dominated the HLA typing market for transplants, reflecting a significant trend towards the utilization of molecular approaches among end users. This dominance is driven by a concerted emphasis from manufacturers on advancing high-resolution assays within molecular platforms, enhancing the accuracy and reliability of HLA typing for transplantation purposes.
By end user, the independent reference laboratories segment accounted for the largest market share in 2024
The HLA typing for transplant market is segmented based on end users into hospitals & transplant centers, independent reference laboratories, and research laboratories & academic institutes. In 2024, independent reference laboratories are projected to dominate the market, driven by a stronger inclination among diagnostic labs to outsource HLA typing services to biotech firms. This shift is facilitated by the advent of high-resolution molecular techniques and the rising number of strategic partnerships between reference laboratories and transplantation centers, enhancing service efficiency and diagnostic precision.
North America accounted for the largest market share, by region, in 2024.
In 2024, North America dominated the HLA typing market for transplant applications, closely followed by Europe. This trend can be attributed to several factors, including the availability of cutting-edge diagnostic technologies, a robust ecosystem of manufacturers, and a well-established healthcare infrastructure. Furthermore, the region is home to leading biotechnology firms that are active in the R&D of novel HLA alleles. Coupled with rising transplantation rates and supportive reimbursement frameworks, these elements significantly contribute to the market’s expansion in North America.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1—20%, Tier 2—45%, and Tier 3—35%
- By Designation: C-level—35%, Directors—25%, and Others—40%
- By Region: North America—40%, Europe—30%, Asia Pacific—20%, Latin America—5%, and the Middle East & Africa—5%
Some of the prominent players in the HLA typing for transplants market are Thermo Fisher Scientific, Inc. (US), QIAGEN (Germany), Illumina (US), CareDx, Inc. (US), Immucor, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Werfen (US), and TBG Biotechnology Corporation (Taiwan).
Research Coverage
This report studies the HLA typing for transplant market based on product& service, technology, transplant type, application, end-user, and region. It studies major factors (such as drivers and restraints) affecting market growth. The report also analyzes market opportunities and challenges for stakeholders and details the competitive landscape for market leaders. It is with respect to their growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.
Rationale to Buy the Report
The report will enable established and entrants/smaller firms to gauge the market’s pulse, which, in turn, would help them gain a larger market share. Firms purchasing the report could use one or a combination of the strategies mentioned below to strengthen their market presence.
This report provides insights into the following pointers:
- Analysis of key drivers ( increasing transplantation rates, growing technological advancements, increasing government initiatives to boost HLA typing services in transplantation) restraints (high cost of molecular test use in HLA typing procedures), opportunities (technological shift from non-molecular serological assay to molecular assay, high growth offered by emerging markets), and challenges (Significant gap between number of organ donors and transplant recipients) influencing the growth of HLA typing for transplant market
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the HLA typing for transplant market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the HLA typing for transplant market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the HLA typing for transplant market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
Table of Contents
1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.3 STUDY SCOPE 27
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 27
1.3.2 INCLUSIONS & EXCLUSIONS 28
1.3.3 YEARS CONSIDERED 29
1.3.4 CURRENCY CONSIDERED 29
1.4 STAKEHOLDERS 29
1.5 SUMMARY OF CHANGES 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
2.1.1 SECONDARY DATA 32
2.1.1.1 Key secondary sources 32
2.1.1.2 Key objectives of secondary research 32
2.1.2 PRIMARY DATA 33
2.1.2.1 Key primary sources 33
2.1.2.2 Key objectives of primary research 33
2.1.2.3 Key insights from primary experts 34
2.1.2.4 Breakdown of primaries 34
2.2 MARKET SIZE ESTIMATION 35
2.2.1 MARKET ESTIMATION APPROACH 36
2.2.1.1 Company revenue-based market estimation approach
top-down approach 37
2.2.1.2 Procedure-based market estimation bottom-up approach 38
2.2.1.3 Growth forecast 39
2.2.1.4 CAGR projections 40
2.3 DATA TRIANGULATION 40
2.4 MARKET SHARE ESTIMATION 42
2.5 STUDY ASSUMPTIONS 42
2.5.1 MARKET ASSUMPTIONS 42
2.5.2 GROWTH RATE ASSUMPTIONS 43
2.6 RISK ANALYSIS 43
2.7 RESEARCH LIMITATIONS 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 47
4.1 HLA TYPING FOR TRANSPLANT MARKET OVERVIEW 47
4.2 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET,
BY PRODUCT & SERVICE AND COUNTRY, 2024 48
4.3 HLA TYPING FOR TRANSPLANT MARKET: EMERGING VS. DEVELOPED MARKETS,
2025 VS. 2030 (USD MILLION) 49
4.4 HLA TYPING FOR TRANSPLANT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
5.2.1 DRIVERS 52
5.2.1.1 Rising number of organ donors and transplant procedures 52
5.2.1.2 Surge in organ failure cases due to increased prevalence
of chronic diseases 52
5.2.1.3 Increasing research activities and rising funding for
organ transplantations 53
5.2.1.4 Growing adoption of HLA typing in personalized medicines 53
5.2.2 RESTRAINTS 54
5.2.2.1 High costs of HLA typing products 54
5.2.2.2 Shortage of healthy organs for transplants 54
5.2.3 OPPORTUNITIES 54
5.2.3.1 Adoption of NGS and automation for high-throughput needs 54
5.2.3.2 Use of AI and ML in HLA typing for better accuracy and broader clinical utility 55
5.2.4 CHALLENGES 55
5.2.4.1 Regulatory complexities across regions 55
5.2.4.2 Lack of standardization across HLA typing laboratories 56
5.3 REGULATORY ANALYSIS 56
5.3.1 REGULATORY FRAMEWORK 56
5.3.1.1 North America 56
5.3.1.1.1 US 56
5.3.1.1.2 Canada 56
5.3.1.2 Europe 57
5.3.1.2.1 UK 57
5.3.1.2.2 France 57
5.3.1.2.3 Germany 57
5.3.1.3 Asia Pacific 57
5.3.1.3.1 China 57
5.3.1.3.2 Japan 57
5.3.1.3.3 India 58
5.3.1.4 Latin America 58
5.3.1.4.1 Brazil 58
5.3.1.4.2 Mexico 58
5.3.1.5 Middle East & Africa 58
5.3.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 59
5.4 VALUE CHAIN ANALYSIS 60
5.4.1 RESEARCH & DEVELOPMENT 61
5.4.2 RAW MATERIAL PROCUREMENT & PRODUCT DEVELOPMENT 61
5.4.3 MARKETING, SALES, AND DISTRIBUTION, AND AFTERMARKET SERVICE 61
5.5 SUPPLY CHAIN ANALYSIS 62
5.5.1 PROMINENT COMPANIES 62
5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES 63
5.5.3 SALES & DISTRIBUTION AGENTS 63
5.5.4 END USERS 63
5.6 ECOSYSTEM ANALYSIS 63
5.6.1 ROLE IN ECOSYSTEM 64
5.7 TRADE ANALYSIS 65
5.7.1 IMPORT SCENARIO FOR HS CODE 3822, 2020–2024 65
5.7.2 EXPORT SCENARIO FOR HS CODE 3822, 2020–2024 66
5.8 PATENT ANALYSIS 68
5.8.1 LIST OF MAJOR PATENTS/PATENT APPLICATIONS 69
5.9 PRICING ANALYSIS 70
5.9.1 AVERAGE SELLING PRICING TREND OF INSTRUMENTS, BY TYPE, 2023–2024 70
5.9.2 AVERAGE SELLING PRICING TREND OF NEXT-GENERATION SEQUENCING INSTRUMENTS, BY KEY PLAYER, 2023–2024 71
5.9.3 AVERAGE SELLING PRICING TREND OF REAGENTS, BY TYPE, 2022–2024 71
5.10 TECHNOLOGY ANALYSIS 73
5.10.1 KEY TECHNOLOGIES 73
5.10.1.1 Next-generation sequencing 73
5.10.1.2 PCR-Sequence-specific oligonucleotide probes 73
5.10.2 COMPLEMENTARY TECHNOLOGIES 73
5.10.2.1 Single antigen-based assays 73
5.10.2.2 Flow cytometry crossmatch 74
5.10.3 ADJACENT TECHNOLOGIES 74
5.10.3.1 Bioinformatics software 74
5.11 PORTER’S FIVE FORCE ANALYSIS 74
5.11.1 THREAT OF NEW ENTRANTS 75
5.11.2 THREAT OF SUBSTITUTES 76
5.11.3 BARGAINING POWER OF SUPPLIERS 76
5.11.4 BARGAINING POWER OF BUYERS 76
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 76
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 76
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 76
5.12.2 KEY BUYING CRITERIA 77
5.13 KEY CONFERENCES & EVENTS IN 2024–2025 78
5.14 CASE STUDY ANALYSIS 79
5.14.1 THERMO FISHER SCIENTIFIC TO DEVELOP TECHNIQUES FOR
ENHANCING HLA TYPING ACCURACY IN TRANSPLANTATION 79
5.14.2 ILLUMINA TO STREAMLINE HLA TYPING WITH TRUSIGHT HLA SOLUTION 79
5.14.3 WERFEN TO ACCELERATE HLA TYPING WITH NANOPORE SEQUENCING 80
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 80
5.16 INVESTMENT & FUNDING SCENARIO 81
5.17 UNMET NEEDS 83
5.18 IMPACT OF AI/GEN AI ON HLA TYPING FOR TRANSPLANT MARKET 83
5.18.1 MARKET POTENTIAL OF HLA TYPING PRODUCTS FOR
PRE-TRANSPLANT EVALUATION 83
5.18.1.1 AI use cases in HLA typing for transplant market 84
5.18.1.2 Key companies implementing AI 84
5.18.2 FUTURE OF AI IN HLA TYPING FOR TRANSPLANT MARKET 84
5.19 IMPACT OF 2025 US TARIFF ON HLA TYPING FOR TRANSPLANT MARKET 85
5.19.1 INTRODUCTION 85
5.19.2 KEY TARIFF RATES 85
5.19.3 PRICE IMPACT ANALYSIS 86
5.19.4 IMPACT ON COUNTRY/REGION 86
5.19.4.1 North America 86
5.19.4.1.1 US 86
5.19.4.2 Europe 86
5.19.4.3 Asia Pacific 86
5.19.5 IMPACT ON END-USE INDUSTRIES 87
6 HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE 88
6.1 INTRODUCTION 89
6.2 REAGENTS & CONSUMABLES 89
6.2.1 AVAILABILITY OF MULTIPLE VARIETIES OF REAGENTS & CONSUMABLES TO DRIVE ADOPTION IN HLA TYPING PHASES 89
6.3 INSTRUMENTS 90
6.3.1 NEED FOR PRECISE AND RELIABLE HLA MATCHING IN BONE MARROW AND ORGAN TRANSPLANTS TO PROPEL MARKET GROWTH 90
6.4 SOFTWARE & SERVICES 91
6.4.1 GROWING AUTOMATION AND DIGITALIZATION OF
DIAGNOSTIC LABORATORY PROCEDURES TO AID MARKET GROWTH 91
7 HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY 93
7.1 INTRODUCTION 94
7.2 MOLECULAR ASSAYS 95
7.2.1 PCR-BASED MOLECULAR ASSAYS 96
7.2.1.1 Sequence-specific primer-PCR 97
7.2.1.1.1 Cost-effectiveness and high accuracy to drive identification of HLA variants at low to intermediate resolutions 97
7.2.1.2 Sequence-specific oligonucleotide-PCR 98
7.2.1.2.1 Development and commercialization of innovative sequence-specific oligonucleotide-PCR products to aid segment growth 98
7.2.1.3 Real-time PCR 99
7.2.1.3.1 High sensitivity, effective real-time DNA amplification monitoring, and minimal sample need to drive segment 99
7.2.1.4 Other PCR-based molecular assays 100
7.3 SEQUENCING-BASED MOLECULAR ASSAYS 101
7.3.1 SANGER SEQUENCING 102
7.3.1.1 High accuracy and single-base resolution to detect allelic variants and confirm novel or rare alleles 102
7.3.2 NEXT-GENERATION SEQUENCING 103
7.3.2.1 Growing reliance on outsourcing in-house analysis to propel demand in tissue typing 103
7.3.3 OTHER SEQUENCING-BASED MOLECULAR ASSAYS 104
7.4 NON-MOLECULAR ASSAYS 105
7.4.1 LOWER COSTS AND HIGHER SPECIFICITY TO DRIVE ADOPTION OVER MOLECULAR ASSAYS 105
8 HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION 106
8.1 INTRODUCTION 107
8.2 DIAGNOSTIC APPLICATIONS 107
8.2.1 ANTIBODY SCREENING 108
8.2.1.1 Advancement in pre-transplant compatibility screening with NGS to aid segment growth 108
8.2.2 CHIMERISM MONITORING 109
8.2.2.1 Growing trend of personalized transplant medicine for effective post-procedural clinical risk management to fuel adoption 109
8.2.3 OTHER DIAGNOSTIC APPLICATIONS 110
8.3 RESEARCH APPLICATIONS 111
8.3.1 INCREASING PUBLIC-PRIVATE INVESTMENTS FOR TRANSPLANT DIAGNOSTICS RESEARCH TO FAVOR MARKET GROWTH 111
9 HLA TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE 112
9.1 INTRODUCTION 113
9.2 SOLID ORGAN TRANSPLANTS 113
9.2.1 HIGH POPULARITY OF ORGAN DONATION AND FAVORABLE GOVERNMENT INITIATIVES TO DRIVE MARKET 113
9.3 SOFT-TISSUE TRANSPLANTS 114
9.3.1 NEED FOR HLA TYPING IN COMPOSITE TISSUE ALLOTRANSPLANTATION
TO AID ADOPTION 114
9.4 STEM CELL TRANSPLANTS 115
9.4.1 EXPANDING DIVERSITY OF DONOR REGISTRIES TO FUEL ADOPTION OF
HLA TYPING 115
10 HLA TYPING FOR TRANSPLANT MARKET, BY END USER 117
10.1 INTRODUCTION 118
10.2 INDEPENDENT REFERENCE LABORATORIES 118
10.2.1 ADHERENCE TO QUALITY AND REGULATORY STANDARDS WITH HIGH-QUALITY SERVICES TO DRIVE MARKET GROWTH 118
10.3 HOSPITALS & TRANSPLANT CENTERS 119
10.3.1 DEVELOPED HEALTHCARE INFRASTRUCTURE AND HIGH SUCCESS RATES
IN TRANSPLANT PROCEDURES TO DRIVE MARKET 119
10.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES 120
10.4.1 INCREASING COLLABORATIONS TO DEVELOP AND OPTIMIZE HLA TYPING FOR BETTER ACCURACY, SPECIFICITY, AND EFFICIENCY 120
11 HLA TYPING FOR TRANSPLANT MARKET, BY REGION 122
11.1 INTRODUCTION 123
11.2 NORTH AMERICA 124
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 124
11.2.2 US 127
11.2.2.1 US to dominate HLA typing for transplant market during forecast period 127
11.2.3 CANADA 129
11.2.3.1 Rising number of solid organ and hematopoietic stem cell transplants to drive market adoption of HLA typing 129
11.3 EUROPE 131
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 131
11.3.2 GERMANY 134
11.3.2.1 High donor registration rates and favorable government initiatives to augment market growth 134
11.3.3 UK 136
11.3.3.1 Strong healthcare infrastructure and centrally coordinated transplant system to foster growth 136
11.3.4 FRANCE 138
11.3.4.1 Growing adoption for donor-recipient compatibility testing to
support market 138
11.3.5 SPAIN 140
11.3.5.1 Increasing popularity of solid organ donation to drive market 140
11.3.6 ITALY 142
11.3.6.1 Supportive government policies and strong healthcare infrastructure to spur market growth 142
11.3.7 REST OF EUROPE 143
11.4 ASIA PACIFIC 145
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 145
11.4.2 CHINA 149
11.4.2.1 Presence of leading global manufacturers of HLA typing products to drive market 149
11.4.3 INDIA 151
11.4.3.1 Rise in transplantation procedures and use of HLA typing for assessing donor-recipient compatibility to spur market growth 151
11.4.4 JAPAN 153
11.4.4.1 Increasing number of solid organ transplantation procedures and rising chronic diseases to favor market growth 153
11.4.5 AUSTRALIA 155
11.4.5.1 Increasing use of genomic testing and analysis and growing government backing for clinical diagnostics to drive market 155
11.4.6 SOUTH KOREA 158
11.4.6.1 Government support and advanced healthcare to drive adoption of NGS HLA typing for better transplant outcomes 158
11.4.7 REST OF ASIA PACIFIC 159
11.5 LATIN AMERICA 161
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 161
11.5.2 BRAZIL 164
11.5.2.1 Growing elderly demographic and increasing funding from leading HLA typing manufacturers to propel market growth 164
11.5.3 MEXICO 165
11.5.3.1 Wide recipient base for organ transplant and rise in medical tourism to fuel market growth 165
11.5.4 REST OF LATIN AMERICA 167
11.6 MIDDLE EAST & AFRICA 169
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 170
11.6.2 GCC COUNTRIES 172
11.6.2.1 Improvements in healthcare infrastructure and focus on specialized medical services to augment market growth 172
11.6.3 REST OF MIDDLE EAST & AFRICA 174
12 COMPETITIVE LANDSCAPE 177
12.1 INTRODUCTION 177
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN 177
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN
HLA TYPING FOR TRANSPLANT MARKET 177
12.3 REVENUE ANALYSIS, 2020–2024 179
12.4 MARKET SHARE ANALYSIS, 2024 180
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 182
12.5.1 STARS 182
12.5.2 EMERGING LEADERS 182
12.5.3 PERVASIVE PLAYERS 182
12.5.4 PARTICIPANTS 182
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 184
12.5.5.1 Company footprint 184
12.5.5.2 Region footprint 185
12.5.5.3 Product & service footprint 186
12.5.5.4 Technology footprint 187
12.5.5.5 Application footprint 187
12.5.5.6 End-user footprint 188
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 189
12.6.1 PROGRESSIVE COMPANIES 189
12.6.2 RESPONSIVE COMPANIES 189
12.6.3 DYNAMIC COMPANIES 189
12.6.4 STARTING BLOCKS 189
12.6.5 COMPANY BENCHMARKING: STARTUPS/SMES, 2024 191
12.6.5.1 Detailed list of key startups/SMEs 191
12.6.5.2 Competitive benchmarking of key startups/SMEs 192
12.7 COMPANY VALUATION & FINANCIAL METRICS 193
12.7.1 FINANCIAL METRICS 193
12.7.2 COMPANY VALUATION 193
12.8 BRAND/PRODUCT COMPARISON 194
12.9 COMPETITIVE SCENARIO 195
12.9.1 PRODUCT LAUNCHES AND APPROVALS 195
12.9.2 DEALS 196
13 COMPANY PROFILES 197
13.1 MAJOR PLAYERS 197
13.1.1 THERMO FISHER SCIENTIFIC INC. 197
13.1.1.1 Business overview 197
13.1.1.2 Products/Services/Solutions offered 198
13.1.1.3 Recent developments 199
13.1.1.3.1 Product approvals 199
13.1.1.3.2 Deals 200
13.1.1.3.3 Expansions 201
13.1.1.4 MnM view 201
13.1.1.4.1 Key strengths 201
13.1.1.4.2 Strategic choices 201
13.1.1.4.3 Weaknesses & competitive threats 201
13.1.2 ILLUMINA, INC. 202
13.1.2.1 Business overview 202
13.1.2.2 Products/Services/Solutions offered 204
13.1.2.3 Recent developments 204
13.1.2.3.1 Expansions 204
13.1.2.4 MnM view 205
13.1.2.4.1 Key strengths 205
13.1.2.4.2 Strategic choices 205
13.1.2.4.3 Weaknesses & competitive threats 205
13.1.3 QIAGEN 206
13.1.3.1 Business overview 206
13.1.3.2 Products/Services/Solutions offered 207
13.1.3.3 Recent developments 209
13.1.3.3.1 Product launches 209
13.1.3.3.2 Deals 209
13.1.3.4 MnM view 210
13.1.3.4.1 Key strengths 210
13.1.3.4.2 Strategic choices 210
13.1.3.4.3 Weaknesses & competitive threats 210
13.1.4 BIO-RAD LABORATORIES, INC. 211
13.1.4.1 Business overview 211
13.1.4.2 Products/Services/Solutions offered 212
13.1.4.3 Recent developments 213
13.1.4.3.1 Product launches 213
13.1.4.4 MnM view 213
13.1.4.4.1 Key strengths 213
13.1.4.4.2 Strategic choices 213
13.1.4.4.3 Weaknesses & competitive threats 214
13.1.5 F. HOFFMANN-LA ROCHE LTD. 215
13.1.5.1 Business overview 215
13.1.5.2 Products/Services/Solutions offered 216
13.1.5.3 Recent developments 217
13.1.5.3.1 Expansions 217
13.1.5.4 MnM view 217
13.1.5.4.1 Key strengths 217
13.1.5.4.2 Strategic choices 217
13.1.5.4.3 Weaknesses & competitive threats 218
13.1.6 CAREDX, INC. 219
13.1.6.1 Business overview 219
13.1.6.2 Products/Services/Solutions offered 220
13.1.6.3 Recent developments 221
13.1.6.3.1 Product launches and approvals 221
13.1.6.3.2 Deals 221
13.1.7 WERFEN 222
13.1.7.1 Business overview 222
13.1.7.2 Products/Services/Solutions offered 222
13.1.7.3 Recent developments 223
13.1.7.3.1 Product launches 223
13.1.7.3.2 Deals 223
13.1.8 DIASORIN S.P.A. 224
13.1.8.1 Business overview 224
13.1.8.2 Products/Services/Solutions offered 225
13.1.8.3 Recent developments 226
13.1.8.3.1 Product approvals 226
13.1.9 TBG BIOTECHNOLOGY CORP. 227
13.1.9.1 Business overview 227
13.1.9.2 Products/Services/Solutions offered 227
13.1.9.3 Recent developments 228
13.1.9.3.1 Product approvals 228
13.1.9.3.2 Deals 228
13.1.10 FUJIREBIO 229
13.1.10.1 Business overview 229
13.1.10.2 Products/Services/Solutions offered 229
13.1.10.3 Recent developments 230
13.1.10.3.1 Deals 230
13.1.11 BECTON, DICKINSON AND COMPANY 231
13.1.11.1 Business overview 231
13.1.11.2 Products/Services/Solutions offered 233
13.1.12 EUROBIO SCIENTIFIC 234
13.1.12.1 Business overview 234
13.1.12.2 Products/Services/Solutions offered 235
13.1.12.3 Recent developments 235
13.1.12.3.1 Product launches and approvals 235
13.1.12.3.2 Deals 236
13.1.13 PACBIO 237
13.1.13.1 Business overview 237
13.1.13.2 Products/Services/Solutions offered 239
13.1.13.3 Recent developments 239
13.1.13.3.1 Product approvals and updates 239
13.1.13.3.2 Deals 240
13.1.14 BAG DIAGNOSTICS GMBH 241
13.1.14.1 Business overview 241
13.1.14.2 Products/Services/Solutions offered 241
13.1.15 CREATIVE BIOLABS 242
13.1.15.1 Business overview 242
13.1.15.2 Products/Services/Solutions offered 242
13.2 OTHER PLAYERS 243
13.2.1 HISTOGENETICS LLC 243
13.2.2 SCISCO GENETICS, INC. 244
13.2.3 INNO-TRAIN DIAGNOSTIK GMBH 245
13.2.4 BIONOBIS 246
13.2.5 TAKARA BIO INC. 247
13.2.6 KRISHGEN BIOSYSTEMS 248
13.2.7 SCIENCELL RESEARCH LABORATORIES, INC. 249
13.2.8 PROIMMUNE LTD. 250
13.2.9 ALPHA BIOTECH LIMITED 251
13.2.10 BIOFORTUNA LIMITED 252
14 APPENDIX 253
14.1 DISCUSSION GUIDE 253
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 257
14.3 CUSTOMIZATION OPTIONS 259
14.4 RELATED REPORTS 259
14.5 AUTHOR DETAILS 260
LIST OF TABLES
TABLE 1 HLA TYPING FOR TRANSPLANT MARKET: INCLUSIONS & EXCLUSIONS 28
TABLE 2 HLA TYPING FOR TRANSPLANT MARKET ASSUMPTIONS 42
TABLE 3 HLA TYPING FOR TRANSPLANT MARKET: RISK ANALYSIS 43
TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 59
TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 59
TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 59
TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS 60
TABLE 8 HLA TYPING MARKET: ROLE IN ECOSYSTEM 64
TABLE 9 HLA TYPING FOR TRANSPLANT MARKET: IMPORT SCENARIO FOR
HS CODE 3822, BY COUNTRY, 2020–2024 (USD THOUSAND) 66
TABLE 10 HLA TYPING FOR TRANSPLANT MARKET: EXPORT SCENARIO FOR
HS CODE 3822, BY COUNTRY, 2020–2024 (USD THOUSAND) 67
TABLE 11 HLA TYPING FOR TRANSPLANT MARKET: LIST OF MAJOR PATENTS/
PATENT APPLICATIONS 69
TABLE 12 AVERAGE SELLING PRICING TREND OF NEXT-GENERATION SEQUENCING INSTRUMENTS, BY KEY PLAYER, 2023–2024 (USD) 71
TABLE 13 AVERAGE SELLING PRICING TREND OF INSTRUMENTS AND REAGENTS,
BY REGION, 2022–2024 (USD THOUSAND) 72
TABLE 14 HLA TYPING FOR TRANSPLANT MARKET: PORTERS FIVE FORCES 74
TABLE 15 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS,
BY PRODUCT & SERVICE (%) 77
TABLE 16 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
FOR MAJOR END USERS 78
TABLE 17 HLA TYPING FOR TRANSPLANT MARKET: LIST OF KEY CONFERENCES &
EVENTS, JANUARY 2025–DECEMBER 2026 78
TABLE 18 THERMO FISHER SCIENTIFIC TO DEVELOP TECHNIQUES FOR ENHANCING
HLA TYPING ACCURACY IN TRANSPLANTATION 79
TABLE 19 ILLUMINA TO STREAMLINE HLA TYPING WITH TRUSIGHT HLA SOLUTION 79
TABLE 20 WERFEN TO ACCELERATE HLA TYPING WITH NANOPORE SEQUENCING 80
TABLE 21 HLA TYPING FOR TRANSPLANT MARKET: UNMET NEEDS 83
TABLE 22 HLA TYPING FOR TRANSPLANT MARKET: KEY COMPANIES IMPLEMENTING AI 84
TABLE 23 US ADJUSTED RECIPROCAL TARIFF RATES 85
TABLE 24 HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 89
TABLE 25 HLA TYPING FOR TRANSPLANT MARKET FOR REAGENTS & CONSUMABLES,
BY REGION, 2023–2030 (USD MILLION) 90
TABLE 26 HLA TYPING FOR TRANSPLANT MARKET FOR INSTRUMENTS, BY REGION,
2023–2030 (USD MILLION) 91
TABLE 27 HLA TYPING FOR TRANSPLANT MARKET FOR SOFTWARE & SERVICES,
BY REGION, 2023–2030 (USD MILLION) 92
TABLE 28 HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 94
TABLE 29 HLA TYPING FOR TRANSPLANT TECHNOLOGY MARKET, BY REGION,
2023–2030 (USD MILLION) 94
TABLE 30 HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 95
TABLE 31 HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY REGION, 2023–2030 (USD MILLION) 96
TABLE 32 PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION) 97
TABLE 33 PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION,
2023–2030 (USD MILLION) 97
TABLE 34 SEQUENCE-SPECIFIC PRIMER-PCR MARKET, BY REGION,
2023–2030 (USD MILLION) 98
TABLE 35 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR MARKET, BY REGION,
2023–2030 (USD MILLION) 99
TABLE 36 REAL-TIME PCR MARKET, BY REGION, 2023–2030 (USD MILLION) 100
TABLE 37 OTHER PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION,
2023–2030 (USD MILLION) 101
TABLE 38 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 102
TABLE 39 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION,
2023–2030 (USD MILLION) 102
TABLE 40 SANGER SEQUENCING MARKET, BY REGION, 2023–2030 (USD MILLION) 103
TABLE 41 NEXT-GENERATION SEQUENCING MARKET, BY REGION,
2023–2030 (USD MILLION) 104
TABLE 42 OTHER SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION,
2023–2030 (USD MILLION) 104
TABLE 43 HLA TYPING FOR TRANSPLANT MARKET FOR NON-MOLECULAR ASSAYS,
BY REGION, 2023–2030 (USD MILLION) 105
TABLE 44 HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 107
TABLE 45 HLA TYPING FOR TRANSPLANT MARKET FOR DIAGNOSTIC APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 107
TABLE 46 HLA TYPING FOR TRANSPLANT MARKET FOR DIAGNOSTIC APPLICATIONS,
BY REGION, 2023–2030 (USD MILLION) 108
TABLE 47 ANTIBODY SCREENING MARKET, BY REGION, 2023–2030 (USD MILLION) 109
TABLE 48 CHIMERISM MONITORING MARKET, BY REGION, 2023–2030 (USD MILLION) 110
TABLE 49 OTHER DIAGNOSTIC APPLICATIONS MARKET, BY REGION,
2023–2030 (USD MILLION) 110
TABLE 50 HLA TYPING FOR TRANSPLANT MARKET FOR RESEARCH APPLICATIONS,
BY REGION, 2023–2030 (USD MILLION) 111
TABLE 51 HLA TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE,
2023–2030 (USD MILLION) 113
TABLE 52 HLA TYPING FOR SOLID ORGAN TRANSPLANTS MARKET, BY REGION,
2023–2030 (USD MILLION) 114
TABLE 53 HLA TYPING FOR SOFT-TISSUE TRANSPLANTS MARKET, BY REGION,
2023–2030 (USD MILLION) 115
TABLE 54 HLA TYPING FOR STEM CELL TRANSPLANTS MARKET, BY REGION,
2023–2030 (USD MILLION) 116
TABLE 55 HLA TYPING FOR TRANSPLANT MARKET, BY END USER,
2023–2030 (USD MILLION) 118
TABLE 56 HLA TYPING FOR TRANSPLANT MARKET FOR INDEPENDENT REFERENCE LABORATORIES, 2023–2030 (USD MILLION) 119
TABLE 57 HLA TYPING FOR TRANSPLANT MARKET FOR HOSPITALS &
TRANSPLANT CENTERS, 2023–2030 (USD MILLION) 120
TABLE 58 HLA TYPING FOR TRANSPLANT MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, 2023–2030 (USD MILLION) 121
TABLE 59 HLA TYPING FOR TRANSPLANT MARKET, BY REGION, 2023–2030 (USD MILLION) 123
TABLE 60 HLA TYPING FOR TRANSPLANT MARKET: TRANSPLANT VOLUME BY TYPE,
2023 (NUMBER OF TRANSPLANTS) 123
TABLE 61 NORTH AMERICA: KEY MACROINDICATORS 124
TABLE 62 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 126
TABLE 63 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 126
TABLE 64 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 126
TABLE 65 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY END USER,
2023–2030 (USD MILLION) 127
TABLE 66 US: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 128
TABLE 67 US: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 128
TABLE 68 US: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 128
TABLE 69 US: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 129
TABLE 70 CANADA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 130
TABLE 71 CANADA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 130
TABLE 72 CANADA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 130
TABLE 73 CANADA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 131
TABLE 74 EUROPE: KEY MACROINDICATORS 132
TABLE 75 EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 132
TABLE 76 EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 133
TABLE 77 EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 133
TABLE 78 EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY END USER,
2023–2030 (USD MILLION) 134
TABLE 79 GERMANY: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 135
TABLE 80 GERMANY: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 135
TABLE 81 GERMANY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 135
TABLE 82 GERMANY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 136
TABLE 83 UK: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 137
TABLE 84 UK: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 137
TABLE 85 UK: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 137
TABLE 86 UK: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 138
TABLE 87 FRANCE: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 138
TABLE 88 FRANCE: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 139
TABLE 89 FRANCE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 139
TABLE 90 FRANCE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 140
TABLE 91 SPAIN: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 140
TABLE 92 SPAIN: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 141
TABLE 93 SPAIN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 141
TABLE 94 SPAIN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 141
TABLE 95 ITALY: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 142
TABLE 96 ITALY: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 142
TABLE 97 ITALY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 143
TABLE 98 ITALY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 143
TABLE 99 REST OF EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 144
TABLE 100 REST OF EUROPE: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 144
TABLE 101 REST OF EUROPE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 144
TABLE 102 REST OF EUROPE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 145
TABLE 103 ASIA PACIFIC: KEY MACROINDICATORS 146
TABLE 104 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 148
TABLE 105 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 148
TABLE 106 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 149
TABLE 107 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY END USER,
2023–2030 (USD MILLION) 149
TABLE 108 CHINA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 150
TABLE 109 CHINA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 150
TABLE 110 CHINA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 151
TABLE 111 CHINA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 151
TABLE 112 INDIA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 152
TABLE 113 INDIA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 152
TABLE 114 INDIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 153
TABLE 115 INDIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 153
TABLE 116 JAPAN: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 154
TABLE 117 JAPAN: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 154
TABLE 118 JAPAN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 155
TABLE 119 JAPAN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 155
TABLE 120 AUSTRALIA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 156
TABLE 121 AUSTRALIA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 156
TABLE 122 AUSTRALIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 157
TABLE 123 AUSTRALIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 157
TABLE 124 SOUTH KOREA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 158
TABLE 125 SOUTH KOREA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 158
TABLE 126 SOUTH KOREA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 159
TABLE 127 SOUTH KOREA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION) 159
TABLE 128 REST OF ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 160
TABLE 129 REST OF ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 160
TABLE 130 REST OF ASIA PACIFIC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 160
TABLE 131 REST OF ASIA PACIFIC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 161
TABLE 132 LATIN AMERICA: KEY MACROINDICATORS 162
TABLE 133 LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 162
TABLE 134 LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 162
TABLE 135 LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET,
BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 163
TABLE 136 LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY END USER,
2023–2030 (USD MILLION) 163
TABLE 137 BRAZIL: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 164
TABLE 138 BRAZIL: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 164
TABLE 139 BRAZIL: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 165
TABLE 140 BRAZIL: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 165
TABLE 141 MEXICO: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 166
TABLE 142 MEXICO: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 166
TABLE 143 MEXICO: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 167
TABLE 144 MEXICO: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 167
TABLE 145 REST OF LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 168
TABLE 146 REST OF LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 168
TABLE 147 REST OF LATIN AMERICA: PCR-BASED MOLECULAR ASSAYS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 169
TABLE 148 REST OF LATIN AMERICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 169
TABLE 149 MIDDLE EAST & AFRICA: KEY MACROINDICATORS 170
TABLE 150 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY REGION, 2023–2030 (USD MILLION) 170
TABLE 151 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 171
TABLE 152 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 171
TABLE 153 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023–2030 (USD MILLION) 172
TABLE 154 GCC COUNTRIES: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 173
TABLE 155 GCC COUNTRIES: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 173
TABLE 156 GCC COUNTRIES: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 173
TABLE 157 GCC COUNTRIES: SEQUENCING-BASED MOLECULAR ASSAYS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 174
TABLE 158 REST OF MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 174
TABLE 159 REST OF MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 160 REST OF MIDDLE EAST & AFRICA: PCR-BASED MOLECULAR ASSAYS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 161 REST OF MIDDLE EAST & AFRICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION) 176
TABLE 162 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN
HLA TYPING FOR TRANSPLANT MARKET 177
TABLE 163 HLA TYPING FOR TRANSPLANT MARKET: DEGREE OF COMPETITION 180
TABLE 164 HLA TYPING FOR TRANSPLANT MARKET: REGION FOOTPRINT 185
TABLE 165 HLA TYPING FOR TRANSPLANT MARKET: PRODUCT & SERVICE FOOTPRINT 186
TABLE 166 HLA TYPING FOR TRANSPLANT MARKET: TECHNOLOGY FOOTPRINT 187
TABLE 167 HLA TYPING FOR TRANSPLANT MARKET: APPLICATION FOOTPRINT 187
TABLE 168 HLA TYPING FOR TRANSPLANT MARKET: END-USER FOOTPRINT 188
TABLE 169 HLA TYPING FOR TRANSPLANT MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 191
TABLE 170 HLA TYPING FOR TRANSPLANT MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY PRODUCT & SERVICE AND REGION 192
TABLE 171 HLA TYPING FOR TRANSPLANT MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 195
TABLE 172 HLA TYPING FOR TRANSPLANT MARKET: DEALS, JANUARY 2022–APRIL 2025 196
TABLE 173 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 197
TABLE 174 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 198
TABLE 175 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS,
JANUARY 2022–APRIL 2025 199
TABLE 176 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–APRIL 2025 200
TABLE 177 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–APRIL 2025 201
TABLE 178 ILLUMINA, INC.: COMPANY OVERVIEW 202
TABLE 179 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 204
TABLE 180 ILLUMINA, INC.: EXPANSIONS, JANUARY 2022–APRIL 2025 204
TABLE 181 QIAGEN: COMPANY OVERVIEW 206
TABLE 182 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED 207
TABLE 183 QIAGEN: PRODUCT LAUNCHES, JANUARY 2022–APRIL 2025 209
TABLE 184 QIAGEN: DEALS, JANUARY 2022–APRIL 2025 209
TABLE 185 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 211
TABLE 186 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 212
TABLE 187 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022–APRIL 2025 213
TABLE 188 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 215
TABLE 189 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 216
TABLE 190 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2022–APRIL 2025 217
TABLE 191 CAREDX, INC.: COMPANY OVERVIEW 219
TABLE 192 CAREDX, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 220
TABLE 193 CAREDX, INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–APRIL 2025 221
TABLE 194 CAREDX, INC.: DEALS, JANUARY 2022–APRIL 2025 221
TABLE 195 WERFEN: COMPANY OVERVIEW 222
TABLE 196 WERFEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED 222
TABLE 197 WERFEN: PRODUCT LAUNCHES, JANUARY 2022–APRIL 2025 223
TABLE 198 WERFEN: DEALS, JANUARY 2022–APRIL 2025 223
TABLE 199 DIASORIN S.P.A.: COMPANY OVERVIEW 224
TABLE 200 DIASORIN S.P.A.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 225
TABLE 201 DIASORIN S.P.A.: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025 226
TABLE 202 TBG BIOTECHNOLOGY CORP.: COMPANY OVERVIEW 227
TABLE 203 TBG BIOTECHNOLOGY CORP.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 227
TABLE 204 TBG BIOTECHNOLOGY CORP.: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025 228
TABLE 205 TBG BIOTECHNOLOGY CORP.: DEALS, JANUARY 2022–APRIL 2025 228
TABLE 206 FUJIREBIO: COMPANY OVERVIEW 229
TABLE 207 FUJIREBIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED 229
TABLE 208 FUJIREBIO: DEALS, JANUARY 2022–APRIL 2025 230
TABLE 209 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 231
TABLE 210 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED 233
TABLE 211 EUROBIO SCIENTIFIC: COMPANY OVERVIEW 234
TABLE 212 EUROBIO SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED 235
TABLE 213 EUROBIO SCIENTIFIC: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–APRIL 2025 235
TABLE 214 EUROBIO SCIENTIFIC: DEALS, JANUARY 2022–APRIL 2025 236
TABLE 215 PACBIO: COMPANY OVERVIEW 237
TABLE 216 PACBIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED 239
TABLE 217 PACBIO: PRODUCT APPROVALS AND UPDATES, JANUARY 2022–APRIL 2025 239
TABLE 218 PACBIO: DEALS, JANUARY 2022–APRIL 2025 240
TABLE 219 BAG DIAGNOSTICS GMBH: COMPANY OVERVIEW 241
TABLE 220 BAG DIAGNOSTICS GMBH: PRODUCTS/SERVICES/SOLUTIONS OFFERED 241
TABLE 221 CREATIVE BIOLABS: COMPANY OVERVIEW 242
TABLE 222 CREATIVE BIOLABS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 242
TABLE 223 HISTOGENETICS LLC: COMPANY OVERVIEW 243
TABLE 224 SCISCO GENETICS, INC.: COMPANY OVERVIEW 244
TABLE 225 INNO-TRAIN DIAGNOSTIK GMBH: COMPANY OVERVIEW 245
TABLE 226 BIONOBIS: COMPANY OVERVIEW 246
TABLE 227 TAKARA BIO INC.: COMPANY OVERVIEW 247
TABLE 228 KRISHGEN BIOSYSTEMS: COMPANY OVERVIEW 248
TABLE 229 SCIENCELL RESEARCH LABORATORIES, INC.: COMPANY OVERVIEW 249
TABLE 230 PROIMMUNE LTD.: COMPANY OVERVIEW 250
TABLE 231 ALPHA BIOTECH LIMITED: COMPANY OVERVIEW 251
TABLE 232 BIOFORTUNA LIMITED: COMPANY OVERVIEW 252
LIST OF FIGURES
FIGURE 1 HLA TYPING FOR TRANSPLANT MARKET SEGMENTATION & REGIONAL SCOPE 27
FIGURE 2 HLA TYPING FOR TRANSPLANT MARKET: YEARS CONSIDERED 29
FIGURE 3 HLA TYPING FOR TRANSPLANT MARKET: RESEARCH DESIGN 31
FIGURE 4 HLA TYPING FOR TRANSPLANT MARKET: KEY PRIMARY SOURCES 33
FIGURE 5 HLA TYPING FOR TRANSPLANT MARKET: KEY INSIGHTS FROM PRIMARIES 34
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND
DEMAND-SIDE PARTICIPANTS 34
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 35
FIGURE 8 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 36
FIGURE 9 MARKET SIZE ESTIMATION FOR HLA TYPING FOR TRANSPLANT MARKET:
COMPANY REVENUE ESTIMATION 37
FIGURE 10 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF
THERMO FISHER SCIENTIFIC INC. (2024) 38
FIGURE 11 HLA TYPING FOR TRANSPLANT MARKET: COMPANY REVENUE- AND PROCEDURE-BASED MARKET ESTIMATION APPROACH 39
FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 40
FIGURE 13 HLA TYPING FOR TRANSPLANT MARKET: DATA TRIANGULATION 41
FIGURE 14 HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE,
2025 VS. 2030 (USD MILLION) 44
FIGURE 15 HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2025 VS. 2030 (USD MILLION) 45
FIGURE 16 HLA TYPING FOR TRANSPLANT MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 45
FIGURE 17 HLA TYPING FOR TRANSPLANT MARKET: REGIONAL SNAPSHOT 46
FIGURE 18 IMPROVED HEALTHCARE INFRASTRUCTURE AND FAVORABLE GOVERNMENT INITIATIVES TO DRIVE MARKET 47
FIGURE 19 US AND REAGENTS & CONSUMABLES SEGMENT ACCOUNTED
FOR LARGEST MARKET SHARE IN 2024 48
FIGURE 20 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES
DURING STUDY PERIOD 49
FIGURE 21 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030 50
FIGURE 22 HLA TYPING FOR TRANSPLANT MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 51
FIGURE 23 HLA TYPING FOR TRANSPLANT MARKET: VALUE CHAIN ANALYSIS 61
FIGURE 24 HLA TYPING FOR TRANSPLANT MARKET: SUPPLY CHAIN ANALYSIS 62
FIGURE 25 HLA TYPING FOR TRANSPLANT MARKET: ECOSYSTEM ANALYSIS 64
FIGURE 26 HLA TYPING FOR TRANSPLANT MARKET: IMPORT SCENARIO FOR
HS CODE 3822 (2020–2024) 65
FIGURE 27 HLA TYPING FOR TRANSPLANT MARKET: IMPORT SCENARIO FOR
HS CODE 3822 (2020–2024) 67
FIGURE 28 HLA TYPING FOR TRANSPLANT MARKET: TOP PATENT APPLICANTS/
OWNERS (JANUARY 2014–DECEMBER 2025) 68
FIGURE 29 AVERAGE SELLING PRICING TREND OF INSTRUMENTS, BY TYPE,
2023–2024 (USD THOUSAND) 70
FIGURE 30 AVERAGE SELLING PRICING TREND OF REAGENTS, BY TYPE,
2022–2024 (USD THOUSAND) 71
FIGURE 31 AVERAGE SELLING PRICING TREND OF INSTRUMENTS, BY REGION,
2022–2024 (USD THOUSAND) 72
FIGURE 32 HLA TYPING FOR TRANSPLANT MARKET: PORTER’S FIVE FORCES ANALYSIS 75
FIGURE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS,
BY PRODUCT & SERVICE 77
FIGURE 34 KEY BUYING CRITERIA FOR MAJOR END USERS 77
FIGURE 35 HLA TYPING FOR TRANSPLANT MARKET: TRENDS/DISRUPTIONS I
MPACTING CUSTOMERS’ BUSINESSES 81
FIGURE 36 HLA TYPING FOR TRANSPLANT MARKET: FUNDING AND NUMBER
OF DEALS, 2019–2023 81
FIGURE 37 HLA TYPING FOR TRANSPLANT MARKET: NUMBER OF DEALS,
BY KEY PLAYER, 2019–2023 82
FIGURE 38 HLA TYPING FOR TRANSPLANT MARKET: VALUE OF DEALS,
BY KEY PLAYER, 2019–2023 (USD) 82
FIGURE 39 AI USE CASES IN HLA TYPING FOR TRANSPLANT MARKET 84
FIGURE 40 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET SNAPSHOT 125
FIGURE 41 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET SNAPSHOT 147
FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS IN HLA TYPING FOR
TRANSPLANT MARKET (2020–2024) 179
FIGURE 43 MARKET SHARE ANALYSIS OF PLAYERS IN HLA TYPING FOR
TRANSPLANT MARKET (2024) 180
FIGURE 44 HLA TYPING FOR TRANSPLANT MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 183
FIGURE 45 HLA TYPING FOR TRANSPLANT MARKET: COMPANY FOOTPRINT 184
FIGURE 46 HLA TYPING FOR TRANSPLANT MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 190
FIGURE 47 EV/EBITDA OF KEY VENDORS 193
FIGURE 48 5-YEAR STOCK BETA OF KEY VENDORS 193
FIGURE 49 HLA TYPING FOR TRANSPLANT MARKET: BRAND/PRODUCT
COMPARATIVE ANALYSIS 194
FIGURE 50 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 198
FIGURE 51 ILLUMINA, INC.: COMPANY SNAPSHOT 203
FIGURE 52 QIAGEN: COMPANY SNAPSHOT 207
FIGURE 53 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 212
FIGURE 54 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 216
FIGURE 55 CAREDX, INC.: COMPANY SNAPSHOT 220
FIGURE 56 DIASORIN S.P.A.: COMPANY SNAPSHOT 225
FIGURE 57 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 232
FIGURE 58 EUROBIO SCIENTIFIC: COMPANY SNAPSHOT 234
FIGURE 59 PACBIO: COMPANY SNAPSHOT 238
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | USD9,150 | USD9,650 | USD11,500 |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- LNGステーション市場 – 2030年までの世界予測 2025-06-16
- アジア太平洋（APAC）ミサイル市場 – 2030年までの地域予測 2025-06-13
- 高圧洗浄機市場 – 2030年までの世界予測 2025-06-12
- 装甲車両市場 – 2030年までの世界予測 2025-06-12
- 工業用ゴム市場 – 2030年までの世界予測 2025-06-12